CIViC Evidence Items
61 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| D | PTEN | Loss | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | Eichhorn et al., 2008 |
| D | PTEN | Loss AND PIK3CA K111N | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib | Eichhorn et al., 2008 |
| D | PTEN | Loss | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib,Lapatinib | Eichhorn et al., 2008 |
| D | PTEN | Loss | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib,Trastuzumab | Eichhorn et al., 2008 |
| D | PTEN | Loss | Predictive | Supports | Resistance | Stomach Cancer | Docetaxel | Li et al., 2013 |
| B | PTEN | Loss | Predictive | Supports | Resistance | Breast Cancer | Trastuzumab | Dillon et al., 2014 |
| D | PTEN | Loss | Predictive | Supports | Sensitivity/Response | Stomach Cancer | Docetaxel,Capivasertib | Li et al., 2013 |
| C | PTEN | Expression | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Fulvestrant,Everolimus | Sun et al., 2016 |
| C | PTEN | R173C | Oncogenic | Supports | Oncogenicity | Endometrial Hyperplasia | Maxwell et al., 1998 | |
| D | PTEN | Loss | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | PI-103 | O'Brien et al., 2010 |
| D | PTEN | Loss | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | PI3Ka/Di | O'Brien et al., 2010 |
Page 2 of 2